Stock Financial Ratios, Dividends, Split History

HTGM / HTG Molecular Diagnostics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)45.28
Enterprise Value ($M)92.10
Book Value ($M)30.97
Book Value / Share1.09
Price / Book-10.02
NCAV ($M)27.79
NCAV / Share0.98
Price / NCAV3.74
Share Statistics
Common Shares Outstanding 28,355,800
Common Stock Shares Outstanding 13,929,763
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)6.20
Return on Assets (ROA)-1.03
Return on Equity (ROE)3.39
Balance Sheet (mrq) ($M)
Quick Ratio9.59
Current Ratio9.79
Income Statement (mra) ($M)
Sales Revenue Goods Net6,797,255.00
Sales Revenue Services Net7,962,312.00
Sales Revenue Net14,759,567.00
Operating Income-17.72
Net Income-18.96
Earnings Per Share Basic And Diluted-1.79
Cash Flow Statement (mra) ($M)
Cash From Operations-16.57
Cash from Investing3.28
Cash from Financing-16.57
Identifiers and Descriptors
Central Index Key (CIK)1169987

Split History

Stock splits are used by HTG Molecular Diagnostics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
HTGM : HTG Molecular Diagnostics Stock Analysis and Research Report

2017-10-30 - Asif

HTG Molecular is a commercial stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. Molecular profiling is the collection of information about multiple molecular targets, such as DNA and RNA, also called biomarkers, in a biological sample. Molecular profiling information has many important applications, from basic research to molecular diagnostics in personalized medicine. Its technology can be used throughout that range of applications, which is just one of its many benefits. Its focus is on clinical applications. Its primary customer segments include biopharmaceutical companies, academic research centers and molecular testing laboratories. Historically, molecular profiling has faced several technical challenges in clinical applications. These include (i) limited “multiplexing,” which means only a few biomarkers could be tested in a single sample; (ii) the need for vast amount...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

HTG Molecular: Entering Stage Of Growth And Momentum

2018-06-11 seekingalpha
HTGM develops next generation sequencing (NGS) tools utilized by physicians and patients to create a patient-specific course of treatment. (29-0)

The Eleven: Viking Skyrockets, Global Blood Is Fueling

2018-06-04 seekingalpha
The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk tolerance. The first five picks are the top picks (in no particular order). Risks are increased the further away a stock sits from the middle (Picks #6, in the middle of the list, is the least risky). (96-6)

HTG Molecular Diagnostics' (HTGM) CEO T. J. Johnson on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good day, and welcome to the HTG Molecular Diagnostics' First Quarter 2018 Earnings Conference Call. Today's conference is being recorded. (29-1)

2 Attractive Biotechs Under $5

2018-04-23 seekingalpha
Today we cover two attractive healthcare plays whose stocks happen to be currently selling under $5 a share. (48-3)

BRIEF-HTG Molecular Diagnostics Inc Says On March 30, 2018, Co And Qiagen Manchester Limited Entered Second Amendment Of First Statement Of Work

2018-04-04 reuters

CUSIP: 40434H104